Endothelial lipase is increased in vivo by inflammation in humans

Circulation

Volumn 117, Issue 5, 2008, Pages 678-685

  Badellino, Karen O ^a,c   Wolfe, Megan L ^a   Reilly, Muredach P ^a,b   Rader, Daniel J ^a,b  

^a School of Veterinary Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular diseases; Inflammation; Lipids; Obesity

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER;

ADULT; ARTICLE; CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; ENDOTHELIUM CELL; FAMILY HISTORY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; UPREGULATION; BLOOD; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LEPTIN; LIPASE; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 40149083940     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.707349     Document Type: Article

References (54)

1. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999;21:424-428.
2. Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem. 1999;274:14170 -14175.
3. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res. 2002;43:921-929.
4. Ishida T, Choi S, Kundu RK, Hirata K, Rubin EM, Cooper AD, Quertermous T. Endothelial lipase is a major determinant of HDL level. J Clin Invest. 2003;111:347-355.
5. Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM, Rader DJ. Dose-dependent acceleration of highdensity lipoprotein catabolism by endothelial lipase. Circulation. 2003; 108:2121-2126.
6. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111:357-362.
7. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A. 2003;100:2748 -2753.
8. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identification of genetic variants in EL in persons with elevated highdensity lipoprotein cholesterol. Circulation. 2002;106:1321-1326.
9. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 2006;3:e22.
10. Hirata K, Ishida T, Matsushita H, Tsao PS, Quertermous T. Regulated expression of endothelial cell-derived lipase. Biochem Biophys Res Commun. 2000;272:90 -93.
11. Jin W, Sun GS, Marchadier D, Octtaviani E, Glick JM, Rader DJ. Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circ Res. 2003;92:644-650.
12. Lin Y, Rejala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem. 2001;276:42077-42083.
13. Zambon A, Pauletto P, Crepaldi G. Review article: the metabolic syndrome: a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther. 2005;22(suppl 2):20 -23.
14. Valdes AM, Wolfe ML, Tate HC, Gefter W, Rut A, Rader DJ. Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: the Study of the Inherited Risk of Coronary Atherosclerosis. J Invest Med. 2001;49: 353-361.
15. Dekkers PE, Lauw FN, ten Hove T, te Velde AA, Lumley P, Becherer D, van Deventer SJ, van der Poll T. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood. 1999;94: 2252-2258.
16. Taylor FB, Haddad PA, Hack E, Chang AC, Peer GT, Morrissey JH, Li A, Allen RC, Wada H, Kinasewitz GT. Two-stage response to endotoxin infusion into normal human subjects: correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med. 2001;29:326 -334.
17. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab. 2000;85:3770 -3778.
18. Bello N, Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis. 2004;46:287-295.
19. Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M. Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating lipopolysaccharide-induced cytokine secretion in an ex vivo septic model. Shock. 2001;16:340 -343.
20. Maggio M, Basaria S, Ceda GP, Ble A, Ling SM, Bandinelli S, Valenti G, Ferrucci L. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest. 2005;28: 116-119.
21. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90 -119.
22. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 2007;35:1464 -1469.
23. Roberts CK, Won D, Pruthi S, Lin SS, Barnard RJ. Effect of a diet and exercise intervention on oxidative stress, inflammation and monocyte adhesion in diabetic men. Diabetes Res Clin Pract. 2006;73:249 -259.
24. Petersen AMW, Pedersen BK. The anti-inflammatory effects of exercise. J Appl Physiol. 2005;98:1154 -1162.
25. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75: 235-240.
26. Turhan H, Saydam GS, Erbay AR. Ayaz S, Yasar AS, Aksoy Y, Basar N, Yetkin E. Increased plasma soluble adhesion molecules: SICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol. 2006;108:224 -230.
27. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31: 391-398.
28. Weingold B, Ruther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J. 1997;327: 425-429.
29. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257:79-83.
30. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295.
31. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. Science. 2007;317:121-124.
32. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152:593-598.
33. Bouman A, Schipper M, Heineman MJ, Faas MM. Gender difference in the non-specific and specific immune response in humans. Am J Reprod Immunol. 2004;52:19 -26.
34. Chang PY, Wu TL, Tsao KC, Li CC, Sun CF, Wu JT. Microplate ELISAs for soluble VCAM-1 and ICAM-1. Ann Clin Lab Sci. 2005;35:312-317.
35. McConway MG, Johnson D, Kelly A, Griffin D, Smith J, Wallace AM. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem. 2000;37:717-723.
36. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diab Obes Metab. 2006;9:282-289.
37. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499 -508.
38. Ohta T, Saku K, Takata K, Adachi N. Soluble vascular cell-adhesion molecule-1 and soluble intercellular adhesion molecule-1 correlate with lipid and apolipoprotein risk factors for coronary artery disease in children. Eur J Pediatr. 1999;158:592-598.
39. Zuliani G, Volpato S, Ble A, Bandinelli S, Corsi AM, Lauretani F, Paolisso G, Fellin R, Ferrucci L. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis. 2007;192:384 -390.
40. Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szulc A, Jastrzekbska-Maj E, Gasior Z. Hyperlipidaemias and serum cytokines in patients with coronary artery disease. Acta Cardiol. 2003;58:9 -15.
41. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-842.
42. Valle M, Martos R, Gascon F, Canete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Met. 2005;31:55-62.
43. Hergenç G, Schulte H, Assmann G, von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis. 1999;145:147-156.
44. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NFB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296 -1301.
45. Ajuwon KM, Spurlock ME. Adiponectin inhibits lipopolysaccharideinduced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1220-R1225.
46. Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, Schaffler A. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett. 2003;545:103-104.
47. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology. 2004;113: 153-162.
48. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis AJ, Berliner JA. Role of group II secretory phospholipase A2 in atherosclerosis, 2: potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999;19:1291-1298.
49. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol. 2002;22: 1213-1218.
50. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148 -1155.
51. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30:39-49.
52. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res. 1985;26: 1389-1398.
53. Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care. 2006;29:625-630.
54. Noale M, Maggi S, Marzari C, Limongi F, Gallina P, Bianchi D, Crepaldi G, for the ILSA Working Group. Components of the metabolic syndrome and incidence of diabetes in elderly Italians: the Italian Longitudinal Study on Aging. Atherosclerosis. 2006;187:385-392.